SUMMARY OF PRODUCT CHARACTERISTICS. Pharmasin 250 mg/g Premix for medicated feeding stuff for pigs, broilers and pullets

Similar documents
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS 1.B.1 SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8, 10/2012] SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

PART IB1 SUMMARY OF PRODUCT CHARACTERISTICS OCTACILLIN

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

SUMMARY OF PRODUCT CHARACTERISTICS. Cephacare flavour 50 mg tablets for cats and dogs. Excipients: For a full list of excipients, see section 6.1.

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Bottle of powder: Active substance: ceftiofur sodium mg equivalent to ceftiofur...

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. NUFLOR 300 mg/ml solution for injection for cattle and sheep

B. PACKAGE LEAFLET 1

FLOXYME 50 mg/ml SOLUTION FOR USE IN DRINKING WATER

B. PACKAGE LEAFLET 1

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese

SUMMARY OF PRODUCT CHARACTERISTICS. Vetmulin 450 mg/g granules for use in drinking water for pigs. (All MS except FR)

LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/12

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

For the treatment of infections caused by a wide range of Gram-positive and Gramnegative pathogenic bacteria including:

SUMMARY OF THE PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

BOX 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Hymatil 300 mg/ml solution for injection for cattle and sheep Tilmicosin

ANNEX III LABELLING AND PACKAGE LEAFLET

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

Irish Medicines Board

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal product no longer authorised

[09/2018] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

Health Products Regulatory Authority

Summary of Product Characteristics

[Version 7.2, 12/2008] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1/18

SUMMARY OF PRODUCT CHARACTERISTICS. Active substance: cefalexin (as cefalexin monohydrate) mg

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Emdocam 20 mg/ml solution for injection for cattle, pigs and horses

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Ubroseal Dry Cow 2.6 g intramammary suspension for cattle

SUMMARY OF PRODUCT CHARACTERISTICS. Pentoject, Pentobarbitone Sodium 200 mg/ml Solution for Injection

Withdrawal period: 93 days Milk: Not authorised for use in animals producing milk for human consumption.

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Vetoquinol/DOLPAC Small dogs/european Renewal June 2011 SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS. Procaine penicillin Dihydrostreptomycin Sulfate

SUMMARY OF PRODUCT CHARACTERISTICS. Lincomycin (as Lincomycin hydrochloride) Neomycin (as Neomycin sulphate) Excipients Disodium edetate

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

Part II SUMMARY OF PRODUCT CHARACTERISTICS. Each tablet contains 25 mg Clindamycin (as Clindamycin Hydrochloride)

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY of PRODUCT CHARACTERISTICS

Doxivex, 100 mg/ml concentrate for oral solution for chickens and pigs

SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8, 10/2012] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

= 0.5 mg. In vitro toxin neutralisation test based on haemolysis of sheep erythrocytes. For a full list of excipients, see section 6.1.

Summary of Product Characteristics

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

[Version 8.1,01/2017] ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs

Ear drops suspension. A smooth, uniform, white to off-white viscous suspension.

SUMMARY OF PRODUCT CHARACTERISTICS. Florgane 300 mg/ml Suspension for Injection for Cattle and Pigs

SUMMARY OF PRODUCT CHARACTERISTICS

Transcription:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT for medicated feeding stuff for pigs, broilers and pullets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Tylosine (as tylosin phosphate) : 250 mg per g. (equivalent to 250 000 IU) For the full list of excipients see section 6.1 3. PHARMACEUTICAL FORM Premix for medicated feeding stuff. Light tan coloured, free flowing granules. 4. CLINICAL PARTICULARS 4.1 Target species Pigs, broilers and pullets. 4.2 Indications for use (specifying the target species) Pigs - Treatment and prevention of Porcine Intestinal Adenomatosis (Ileitis)associated with Lawsonia intracellularis when the disease has been diagnosed at the group or herd level, - Treatment and prevention of swine dysentery caused by Brachyspira hyodysenteriae when the disease has been diagnosed in the herd. Broilers and pullets: - Treatment and prevention of respiratory infections caused by Mycoplasma gallisepticum and Mycoplasma synoviae, when the disease has been diagnosed in the flock. - Treatment and prevention of necrotic enteritis caused by Clostridium perfringens, when the disease has been diagnosed in the flock. Page 1 of 15

4.3 Contraindications Do not use in animals with known sensitivity to the active substance and/or to any of the excipients of the veterinary medicinal product, Do not use in animals with known hyper sensitivity to tylosin and other macrolides, Do not use where cross-resistance to other macrolides (MLS-resistance)is suspected, Do not use in animals vaccinated with tylosin-sensitive vaccines either at the same time or within 1 week previously. Do not use in animals with hepatic disorders. Do not use in horses. Danger of inflammation of the cecum. 4.4 Special warnings (for each target species) None. 4.5 Special precautions for use 4.5.1 Special precautions for use in animals Animals with acute infections may have a reduced feed intake and should be treated with a suitable injectable product first. Due to likely variability (time, geographical) in susceptibility of bacteria for tylosin, bacteriological sampling and susceptibility testing are recommended. Inappropriate use of the veterinary medicinal product may increase the prevalence of bacteria resistant to Tylosin and other macrolides In farms which have recurring problems with swine dysentery, farm management, livestock husbandry and hygiene should be examined to avoid repeated administration of antimicrobial substances. An eradication procedure should be taken into account. Page 2 of 15

4.5.2 Special precautions for the person administering the veterinary medicinal product to animals Tylosin may induce irritation. Macrolides, such a tylosin, may also cause hypersensitivity (allergy) following injection, inhalation, ingestion or contact with skin or eye. Hypersensitivity to tylosin may lead to cross reactions to other macrolides and vice versa. Allergic reactions to these substances may occasionally be serious and therefore direct contact should be avoided. To avoid exposure during preparation of the medicated feed, wear overalls, safety glasses, impervious gloves, and wear either a disposable half mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 with a filter to EN143. Wash hands after use. In the event of accidental skin contact, wash thoroughly with soap and water. In case of accidental eye contact, flush the eyes with plenty of clean, running water. Do not handle the product if you are allergic to ingredients in the product. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the physician this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention. 4.6 Adverse reactions (frequency and seriousness) In pigs, adverse reactions have been observed, including diarrhoea, pruritus, erythema, rectal oedema and prolapse. 4.7 Use during pregnancy, lactation or lay Laboratory studies in mice and rats have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. No studies have been conducted in the target species population. Use only according to the benefit/risk assessment by the responsible veterinarian. 4.8 Interaction with other medicinal products and other forms of interaction Lincosamides and aminoglycoside antibiotics antagonize the activity of tylosin. 4.9 Amount(s) to be administered and administration route Administration through the feed: for the preparation of a medicated feed containing 40-1100 gram tylosine per ton of feed, the required amount of product should be homogenously mixed with a suitable carrier into a feed premixture so that at least 5 kg of this premixture can be added to the feed in order to obtain a medicated feed with the required concentration. For the preparation of medicated feed: As 1 kg of product contains 250 g tylosin activity it follows that 4 mg Pharmasin 250 mg/g premix corresponds to 1 mg tylosin activity. The dosages are as follows: Page 3 of 15

Pigs For the treatment and prevention of porcine intestinal adenomatosis (PIA): 4 5 mg tylosin per kg BW (corresponding to 16-20 mg product per kg BW) for 3 weeks. For the treatment and prevention of dysentery caused by Brachyspira hyodysenteriae: 4 5 mg tylosin per kg BW (corresponding to 16-20 mg product per kg BW) for 4-5 weeks. It may be necessary to continue treatment until the end of the period of risk (to avoid relapse). or 8 10 mg tylosin per kg BW (corresponding to 32 40 mg product per kg BW) for 8 days, followed by 4-5 mg tylosin per kg BW (corresponding to 16-20 mg product per kg BW) until the end of the period of risk. Broilers and pullets: For the treatment and prevention of respiratory infections: 127 mg tylosin per kg BW (corresponding to 508 mg product per kg BW) for the first 5 days of life. It is strongly recommended to repeat the treatment of the birds at the age of 3-4 weeks. For the treatment and prevention of necrotic enteritis: 10 20 mg tylosin per kg BW (corresponding to 40 80 mg product per kg BW) for 7 days. For the preparation of the medicated feed the body weight of the animals to be treated and their actual daily feed consumption should be taken into due account. Consumption may vary depending on factors like age, breed, husbandry system. To provide the required amount of active substance in mg per kg mixed feed the following calculation should be made:. mg product average body weight (kg) /kg BW/day x of the animals to be treated = mg product Average daily amount of mixed feed intake /kg per animal per kg/ mixed feed The mixing should be performed by an (authorised) feeding stuff manufacturer with adequate mixing apparatus. The uptake of medicated feed depends on the clinical condition of the animals. In order to obtain the correct dosage the concentration of tylosin should be adjusted accordingly. Should there be no clear response to treatment within 3 days the treatment approach should be reconsidered. Body weight should be evaluated accurately to avoid under dosing 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary Tylosin has been shown to produce no adverse effects when fed to pigs at 600 ppm in the feed (three to six times the recommended dose level) for 28 days. At high levels diarrhoea, Page 4 of 15

apathy, convulsions may occur. The therapy is symptomatic. 4.11 Withdrawal period(s) Meat & offal Pig: Zero days Broilers and pullets: 1 day Do not use in laying hens producing eggs for human consumption. 5. PHARMACOLOGICAL OR IMMUNOLOGICAL PROPERTIES ATC Vet Code: Pharmacotherapeutic group: antibacterials for systemic use, macrolides, ATC vet code: QJ01FA90 5.1 Pharmacodynamic properties Tylosin is a macrolide antibiotic produced by a strain of Streptomyces fradiae. It exerts its antimicrobial effect by inhibiting protein synthesis of susceptible micro-organisms. The tylosin spectrum of activity includes Gram-positive bacteria, some Gram negative strains such as Pasteurella, and Mycoplasma spp. at concentrations of 16µg/ml or less. 5.2 Pharmacokinetic properties In most species peak plasma concentrations have been attained 1 to 2 hours after administration of tylosin. Compared to plasma levels clearly higher tissue concentrations have been observed. Tylosin was extensively metabolized. Most of the residues are excreted in faeces predominantly consisting of tylosin A, tylosin factor D and dihydrodesmycosin. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients Wheat meal Dipotassium phosphate (E340) Pregelatinised starch (potato) Page 5 of 15

6.2 Incompatibilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after incorporation into meal or pelleted feed: 3 months. 6.4 Special precautions for storage Store in the original container to protect from light. Store in a dry place. Store below 30 C. Do not refrigerate or freeze. Protect from frost. 6.5 Nature and composition of immediate packaging Low-density polyethylene / paper paper - paper bag of 5 and 20 kg with sutured crimp. 1 kg polyethylene/aluminium foil/polyethylene terephthalate sachet Not all packs may be marketed. 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 7.1 MARKETING AUTHORISATION HOLDER Uitbreidingstraat 80 2600 Antwerpen Belgium 8. MARKETING AUTHORISATION NUMBER(S) 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Page 6 of 15

10. DATE OF REVISION OF THE TEXT PROHIBITION OF SALE, SUPPLY AND/OR USE Consideration should be given to official guidance on the incorporation of medicated premixes in final feed. Page 7 of 15

LABEL 1. NAME OF THE VETERINARY MEDICINAL PRODUCT for medicated feeding stuff for pigs, broilers and pullets Tylosin 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES Tylosin activity (as tylosin phosphate): 250 g per kg (equivalent to 250 000 IU). 3. PHARMACEUTICAL FORM Premix for medicated feeding stuff 4. PACKAGE SIZE 1kg 5 kg 20 kg 5. TARGET SPECIES Pigs, broilers and pullets 6. INDICATION(S) See package leaflet 7. METHOD AND ROUTE(S) OF ADMINISTRATION To be administered through the medicated feed Read the package leaflet before use. 8. WITHDRAWAL PERIOD Meat and offal Pigs: Zero days Broilers and pullets: 1 day Do not use in laying hens producing eggs for human consumption. 9. SPECIAL WARNING(S), IF NECESSARY User Warnings Tylosin may induce irritation. Macrolides, such a tylosin, may also cause hypersensitivity (allergy) following injection, inhalation, ingestion or contact with skin or eye. Hypersensitivity to tylosin may Page 8 of 15

lead to cross reactions to other macrolides and vice versa. Allergic reactions to these substances may occasionally be serious and therefore direct contact should be avoided. To avoid exposure during preparation of the medicated feed, wear overalls, safety glasses, impervious gloves, and wear either a disposable half mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 with a filter to EN143. Wash hands after use. In the event of accidental skin contact, wash thoroughly with soap and water. In case of accidental eye contact, flush the eyes with plenty of clean, running water. Do not handle the product if you are allergic to ingredients in the product. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the physician this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention. 10. EXPIRY DATE <EXP {month/year}> Shelf life after incorporation into meal or pelleted feed: 3 months 11. SPECIAL STORAGE CONDITIONS Store in the original container to protect from light. Store in a dry place. Store below 30 C. Do not refrigerate or freeze. Protect from frost. 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY Disposal: read the package insert. 13. THE WORDS FOR ANIMAL TREATMENT ONLY AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable For animal treatment only to be supplied only on veterinary prescription 14. THE WORDS KEEP OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Uitbreidingstraat 80 2600 Antwerpen Belgium 16. MARKETING AUTHORISATION NUMBER(S) 17. MANUFACTURER S BATCH NUMBER <Batch> <Lot> <BN> {number} Page 9 of 15

PACKAGE LEAFLET for medicated feeding stuff for pigs, broilers and pullets 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder, Uitbreidingstraat 80, 2600 Antwerpen, Belgium Manufacturer for batch release Biovet JSC, 39 Petar Rakov Str, 4550 Peshtera - Bulgaria 2. NAME OF THE VETERINARY MEDICINAL PRODUCT for medicated feeding stuff for pigs, broilers and pullets Tylosin 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Tylosin (as tylosin phosphate) : 250 mg per g. Light tan coloured, free flowing granules. 4. INDICATION(S) Pigs - Treatment and prevention of Porcine Intestinal Adenomatosis (PIA) associated with Lawsonia intracellularis when the disease has been diagnosed at the group or herd level, - Treatment and prevention of swine dysentery caused by Brachyspira hyodysenteriae when the disease has been diagnosed in the herd. Broilers and pullets: - Treatment and prevention of respiratory infections caused by Mycoplasma gallisepticum and Mycoplasma synoviae, when the disease has been diagnosed in the flock. - Treatment and prevention of necrotic enteritis caused by Clostridium perfringens, when the disease has been diagnosed in the flock. 5. CONTRAINDICATIONS Do not use in animals with known sensitivity to the active substance and/or to any of the excipients of the veterinary medicinal product, Do not use in animals with known hyper sensitivity to tylosin and other macrolides, Page 10 of 15

Do not use where cross-resistance to other macrolides (MLS-resistance) is suspected. Do not use in animals vaccinated with tylosin-sensitive vaccines either at the same time or within 1 week previously. Do not use in animals with hepatic disorders. Do not use in horses. Danger of inflammation of the cecum 6. ADVERSE REACTIONS In pigs, adverse reactions have been observed, including diarrhoea, pruritus, erythema, rectal oedema and prolapse. If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon 7. TARGET SPECIES Pigs, broilers and pullets. 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION Administration through the feed: for the preparation of a medicated feed containing 40-1100 gram tylosine per ton of feed, the required amount of should be homogenously mixed with a suitable carrier into a feed premixture so that at least 5 kg of this premixture can be added to the feed in order to obtain a medicated feed with the required concentration. For the preparation of medicated feed: As 1 kg Pharmasin 250 mg/g premix contains 250 g tylosin activity it follows that 4 mg Pharmasin 250 mg/g premix corresponds to 1 mg tylosin activity. The dosages are as follows: Pigs For the treatment and prevention of porcine intestinal adenomatosis (PIA): 4 5 mg tylosin per kg BW (corresponding to 16-20 mg Pharmasin 250 mg/g premix per kg BW) for 3 weeks. For the treatment and prevention of dysentery caused by Brachyspira hyodysenteriae: 4 5 mg tylosin per kg BW (corresponding to 16-20 mg Pharmasin 250 mg/g premix per kg BW) for 4-5 weeks. It may be necessary to continue treatment until the end of the period of risk (to avoid relapse). or 8 10 mg tylosin per kg BW (corresponding to 32 40 mg Pharmasin 250 mg/g premix per kg BW) for 8 days, followed by 4-5 mg tylosin per kg BW (corresponding to 16-20 mg Pharmasin 250 mg/g premix per kg BW) until the end of the period of risk (to avoid relapse). Broilers and pullets For the treatment and prevention of respiratory infections: Page 11 of 15

127 mg tylosin per kg BW (corresponding to 508 mg Pharmasin 250 mg/g premix per kg BW) for the first 5 days of life. It is strongly recommended to repeat the treatment of the birds at the age of 3-4 weeks. For the treatment and prevention of necrotic enteritis: 10 20 mg tylosin per kg BW (corresponding to 40 80 mg Pharmasin 250 mg/g premix per kg BW) for 7 days. For the preparation of the medicated feed the body weight of the animals to be treated and their actual daily feed consumption should be taken into due account. Consumption may vary depending on factors like age, breed, husbandry system. To provide the required amount of active substance in mg per kg mixed feed the following calculation should be made:. mg Pharmasin 250 mg/g average body weight (kg) premix /kg BW/day x of the animals to be treated = mg Pharmasin Average daily amount of mixed feed intake /kg per animal 250 mg/g premix per kg/ mixed feed The mixing should be performed by an (authorised) feeding stuff manufacturer with adequate mixing apparatus. The uptake of medicated feed depends on the clinical condition of the animals. In order to obtain the correct dosage the concentration of tylosin should be adjusted accordingly. Should there be no clear response to treatment within 3 days the treatment approach should be reconsidered. Body weight should be evaluated accurately to avoid under dosing 9. ADVICE ON CORRECT ADMINISTRATION Animals with acute infections may have a reduced feed intake and should be treated with a suitable injectable product first. Due to likely variability (time, geographical) in susceptibility of bacteria for tylosin, bacteriological sampling and susceptibility testing are recommended. Inappropriate use of the veterinary medicinal product may increase the prevalence of bacteria resistant to Tylosin and other macrolides In farms which have recurring problems with swine dysentery, farm management, livestock husbandry and hygiene should be examined to avoid repeated administration of antimicrobial substances. An eradication procedure should be taken into account 10. WITHDRAWAL PERIOD Meat & offal Pig: Zero days Broilers and pullets: 1 day Do not use in laying hens producing eggs for human consumption. 11. SPECIAL STORAGE PRECAUTIONS Page 12 of 15

Keep out of the sight and reach of children. Store in the original container to protect from light. Store in a dry place. Store below 30 C. Do not refrigerate or freeze. Protect from frost. Do not use after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month. Shelf life after incorporation into meal or pelleted feed : 3 months.12. SPECIAL WARNING(S) Special precautions for the person administering the veterinary medicinal product to animals Tylosin may induce irritation. Macrolides, such a tylosin, may also cause hypersensitivity (allergy) following injection, inhalation, ingestion or contact with skin or eye. Hypersensitivity to tylosin may lead to cross reactions to other macrolides and vice versa. Allergic reactions to these substances may occasionally be serious and therefore direct contact should be avoided. To avoid exposure during preparation of the medicated feed, wear overalls, safety glasses, impervious gloves, and wear either a disposable half mask respirator conforming to European Standard EN149 or a non-disposable respirator to European Standard EN140 with a filter to EN143. Wash hands after use. In the event of accidental skin contact, wash thoroughly with soap and water. In case of accidental eye contact, flush the eyes with plenty of clean, running water. Do not handle the product if you are allergic to ingredients in the product. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the physician this warning. Swelling of the face, lips and eyes or difficulty in breathing are more serious symptoms and require urgent medical attention. Use during pregnancy, lactation or lay Laboratory studies in mice and rats have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. No studies have been conducted in the target species population. Use only according to the benefit/risk assessment by the responsible veterinarian Interaction with other medicinal products and other forms of interaction Lincosamides and aminoglycoside antibiotics antagonize the activity of tylosin Overdose Tylosin has been shown to produce no adverse effects when fed to pigs at 600 ppm in the feed (three to six times the recommended dose level) for 28 days. At high levels diarrhoea, apathy, convulsions may occur. The therapy is symptomatic Incompatibilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY Medicines should not be disposed of via wastewater or household waste. Page 13 of 15

Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment. Page 14 of 15

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED 15. OTHER INFORMATION For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder. Low-density polyethylene / paper paper - paper bag of 5 and 20 kg with sutured crimp. 1 kg polyethylene/aluminium foil/polyethylene terephthalate sachet. Not all pack sizes may be marketed. Page 15 of 15